BitcoinBTC, coin
StableETF

REX Shares launches 2x leveraged Strive ETF on Cboe as 21Shares advances Injective ETF filing

REX Shares began trading a 2x leveraged Strive ETF on Cboe on Sept. 18, while 21Shares updated its SEC filing for an Injective ETF specifying Nasdaq as the listing venue.

Why it matters

The two filings represent separate moves in the expanding U.S. leveraged and altcoin ETF product landscape. REX Shares' ASSX adds another single-stock leveraged vehicle to Cboe, while 21Shares' updated Injective filing signals continued institutional interest in tokenized index products with staking components.

Key facts

ASSX began trading on September 18 after Cboe certified the fund for registration on September 15.

Reported by Crypto.News

The fund has a 1.5% total expense ratio with Tuttle Capital Management as adviser.

1.5 %Reported by Crypto.News

Strive held 25,000 BTC after purchasing 469 BTC at an average price of $77,954 per coin.

25,000 BTCReported by Crypto.News

Strive shares closed Friday at $30.09, rising 6.4% during ASSX's first trading session.

30.09 USDReported by Crypto.News

21Shares filed an updated SEC application for an Injective ETF naming Nasdaq Stock Market LLC as the listing venue.

Reported by BTC-ECHO

The updated 21Shares filing switched the benchmark from CME CF Benchmarks to the FTSE Injective Index.

Reported by BTC-ECHO

21Shares plans to stake 40 to 60 percent of the INJ held by the Injective ETF.

Reported by BTC-ECHO

What happened

REX Shares and Tuttle Capital Management launched the T-REX 2X Long ASST Daily Target ETF on Cboe on September 18, seeking twice the daily share performance of Strive Inc., which trades on Nasdaq under the ticker ASST. Crypto.News reported that Cboe certified the fund for registration on September 15, and the exchange listed it three days later. The fund carries a 1.5% total expense ratio, with Tuttle Capital Management as adviser and REX Shares as sponsor. Strive held 25,000 BTC after purchasing 469 BTC at an average price of $77,954 per coin, and its shares closed Friday at $30.09, up 6.4% during ASSX's first trading session. Separately, BTC-ECHO reported that 21Shares filed an updated application with the SEC for an Injective ETF, naming Nasdaq Stock Market LLC as the planned listing venue. The new filing switched the benchmark from CME CF Benchmarks to the FTSE Injective Index and designated Coinbase Custody and BitGo Bank & Trust for INJ custody. 21Shares plans to stake 40 to 60 percent of the INJ held by the fund. The articles cover distinct products from different issuers with no overlapping claims.

How the story developed

  1. Official statement

    Cboe certified ASSX for registration

    A Cboe certification filed with the SEC recorded the exchange's approval for listing and registration of the REX Shares fund.

    Crypto.News

  2. Update

    ASSX began trading on Cboe

    REX Shares and Tuttle Capital Management's 2x leveraged Strive ETF started trading.

    Crypto.News

  3. First report

    First report by Crypto.News

    REX launches 2x Strive ETF ASSX on Cboe

    Crypto.News

  4. Independent corroboration

    Independently corroborated by BTC-ECHO

    21Shares konkretisiert Pläne für Injective ETF

    BTC-ECHO

  5. Update

    21Shares updated its SEC filing for an Injective ETF

    The filing specified Nasdaq as the listing venue, the FTSE Injective Index as the benchmark, and Coinbase Custody and BitGo as custodians.

    BTC-ECHO

How coverage built up

Independent sources over time, counted the way the consensus panel counts them: a republication of a wire story does not move the line.

21 Sept, 04:202 independent sources21 Sept, 09:45
  • 21 Sept 2026, 04:20 UTC: Crypto.News — 1 independent source, 1 reports
  • 21 Sept 2026, 09:45 UTC: BTC-ECHO — 2 independent sources, 2 reports

Affected entities

Also mentioned: Coinbase, Solana, MARA Holdings

Original sources

PublisherReportRolePublished
Crypto.News
Crypto media
REX launches 2x Strive ETF ASSX on CboeOriginal
BTC-ECHO
Crypto media
21Shares konkretisiert Pläne für Injective ETFIndependent